Immutep announces poster presentation for the TACTI-004 Phase III trial
Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...
Nasdaq12d
Immutep Limited to Present TACTI-004 Phase III Trial Data at European Lung Cancer Congress 2025
The TACTI-004 trial evaluates eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. When will the TACTI-004 trial poster be presented? The poster ...